CSIMarket Company Name, Ticker, Competitors, else..
 
Maxcyte inc   (NASDAQ: MXCT)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 
Price: $1.2800 $0.02 1.587%
Day's High: $1.2999999523162842 Week Perf: -0.78 %
Day's Low: $ 1.25 30 Day Perf: 15.32 %
Volume (M): 333,493 52 Wk High: $ 1.87
Volume (M$): $ 0 52 Wk Avg: $1.22
Open: $1.25 52 Wk Low: $0.64



 Market Capitalization (Millions $) 137
 Shares Outstanding (Millions) 107
 Employees 91
 Revenues (TTM) (Millions $) 31
 Net Income (TTM) (Millions $) -36
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 1

Business Description


Maxcyte Inc. is a biotechnology company that specializes in cell engineering and flow electroporation technology. The company is focused on developing innovative solutions for drug discovery, cell and gene therapy, and biomanufacturing. Maxcyte's proprietary technology allows for high levels of transfection efficiency and cell engineering, making it an attractive option for researchers and pharmaceutical companies looking to develop new therapies and improve biomanufacturing processes. The company also offers contract development and manufacturing services, providing support to clients in the development and production of cell-based therapies. Overall, Maxcyte Inc. plays a significant role in advancing the field of cell engineering and facilitating the development of novel therapies.


   Company Address: 9713 Key West Avenue Rockville 20850 MD
   Company Phone Number: 944-1700   Stock Exchange / Ticker: NASDAQ MXCT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
OABI   -3.13%    
BNBX   -6.67%    
ELTX   -15.14%    
MRNA        5.48% 
• View Complete Report
   



Partnership

Pioneering the Future of Medicine MaxCyte and Ori Biotechs Cutting-Edge Collaboration Drives Progress in Cellular Th...

Published Wed, Jun 11 2025 8:55 AM UTC

Revolutionizing Cellular Therapy: MaxCyte and Ori Biotech’s Game-Changing CollaborationIn the fast-paced world of biotechnological innovation, where the stakes are as high as the potential benefits, the partnership between MaxCyte and Ori Biotech emerges as a beacon of transformative potential. With the convergence of advanced platforms, cutting-edge technology, and strat...
Merger and Acquisition

MaxCyte Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments,

Published Thu, Jan 30 2025 7:00 AM UTC

MaxCyte Expands Horizons with SeQure Dx Acquisition Amidst Financial ChallengesIn a noteworthy development within the biotech sector, MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a prominent player in cell-engineering solutions, announced its acquisition of SeQure Dx, a leader in on-target and off-target editing assessment services for cell and gene therapies. The acquisition, u...
Management Announcement

MaxCyte at a Crossroads: Navigating Innovation Amidst Financial Headwinds

Published Mon, Jan 13 2025 8:05 AM UTC

MaxCyte Inc.: A Legacy of Cell Engineering with Financial Challenges AheadMaxCyte, a prominent player in the biopharmaceutical landscape and a pioneer in cell engineering, recently released its preliminary unaudited financial results for the fourth quarter and full year ending December 31, 2024. Despite two decades of innovation, the company stands at a financial crossroads,...
Management Announcement

MaxCyte at 25: Navigating Innovation and Financial Challenges in the Quest for Genetic Cures,

Published Wed, Nov 13 2024 1:05 PM UTC

IntroductionMaxCyte Inc. proudly commemorates 25 years of innovation in the field of cell engineering, a milestone marked by numerous advancements in cell and gene therapy since its inception in 1999. Despite its celebrated history, the company faces challenges, including a significant net loss reported for the second quarter of 2024. However, its recent strategic partnershi...
Contract

MaxCyte and Kamau Therapeutics Join Forces to Uphold Genetic Disease Treatment with Cutting-Edge Ce...

Published Mon, Sep 16 2024 6:00 AM UTC

In an ambitious stride toward transforming the landscape of genetic disease treatment, MaxCyte Inc. a global leader in cell engineering and therapeutic research, has entered into a strategic platform license agreement with Kamau Therapeutics. This collaboration aims to harness MaxCyte’s sophisticated Flow Electroporation technology and ExPERT platform to bolster Kamau s pi...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 4.40
Price to Sales (Expected) -
Price to Book 0.86
PEG (TTM) -

Financial Strength Current
Quick Ratio 10.68
Working Capital Ratio 12.24
Leverage Ratio (MRQ) 0.16
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.33 $
Revenues (TTM) 0.29 $
Cash Flow (TTM) -
Cash 0.99 $
Book Value 1.49 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 341,220
Net Income per Employee (TTM) -391,604
Receivable Turnover Ratio (TTM) 6.22
Inventory Turnover Ratio (TTM) 0.84
Asset Turnover Ratio (TTM) 0.16

Profitability Ratios Current
Gross Margin (MRQ) 76.96 %
Operating Margin (MRQ) -140.72 %
Net Margin (MRQ) -122.05 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Maxcyte Inc's Segments
Product    106.41 % of total Revenue
License    111.68 % of total Revenue
Assay and other service revenue    14.65 % of total Revenue
Cell Engineering Technology Segment    232.73 % of total Revenue
US    154.67 % of total Revenue
Licenses    78.06 % of total Revenue

  Maxcyte Inc Outlook

On March 12 2024 the Maxcyte Inc provided following guidance

MaxCyte Inc, a prominent company specializing in cell-engineering technologies, recently disclosed its financial results for the fourth quarter and full year ending on December 31, 2023. The company, listed on NASDAQ as MXCT and on the London Stock Exchange as MXCT, reported positive financial performance for the period.

The company reconfirmed its projected guidance for the year 2024, emphasizing its commitment to driving advancements in the discovery, development, and commercialization of next-generation cell therapeutics and innovative bioprocessing applications.

The solid financial results and reiterated guidance demonstrate MaxCyte's success in leveraging its enabling platform technologies...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.